Stock Information
 
SEC Filings
 
Financial Information
 
News Releases
 
Presentations & Events
 
Shareholder Services
 
Corporate Governance
 
E-mail Alerts

 

  » BMS.com Home » Investors
 
Company Profile
Bristol-Myers Squibb is a global biopharmaceutical and related health care products company whose mission is to extend and enhance human life. Bristol-Myers Squibb's 42,000 employees are dedicated to discovering, developing and providing innovative medicines that address significant medical needs of patients worldwide. And by living our mission and growing our company for well over a century, we are also making a difference in the lives of our shareholders, employees and neighbors.

Bristol-Myers Squibb Discusses Proposed ImClone Acquisition...WEBCAST...
Thursday, July 31, 2008
Webcast replay >>
Transcript (PDF) >>

Bristol-Myers Squibb 2008 Second Quarter Results
Thursday, July 24, 2008
Webcast replay>>
Press Release (PDF) >>
Press Release (HTML) >>
FAX Package (Excel) >>

08/19/08
Bristol-Myers Squibb and PDL BioPharma Enter Global Alliance to Develop Novel Treatment for Multiple Myeloma
08/13/08
ADDING MULTIMEDIA NJ, CT, NY & MD School Districts Join Program That Teaches High School Students How Medicines Are Made
08/12/08
NJ, CT, NY & MD School Districts Join Program That Teaches High School Students How Medicines Are Made
08/05/08
CORRECTING and REPLACING CASTLE Data Showed Boosted REYATAZ(R) (atazanavir sulfate) and Lopinavir/r Achieved Similar Results for Undetectable Viral Load in Treatment-Naive HIV-1 Infected Patients, Regardless of Gender
08/05/08
BRISTOL-MYERS SQUIBB LAUNCHES SECURE THE FUTURE(R) TECHNICAL ASSISTANCE PROGRAM TO OPTIMIZE COMMUNITY SERVICES FOR COMPREHENSIVE HIV MANAGEMENT IN SUB-SAHARAN AFRICA
08/05/08
CASTLE Data Showed Boosted REYATAZ(R) (atazanavir sulfate) and Lopinavir/r Achieved Similar Results for Undetectable Viral Load in Treatment-Naive HIV-1 Infected Patients, Regardless of Gender
 


[Top Page] [Search] [Index] [Contact] [Home]



Italicized product names are registered trademarks of Bristol-Myers Squibb Company or one of its divisions or subsidiaries. Abilify® is a registered trademark of Otsuka Pharmaceutical Co., Ltd. Erbitux® is a registered trademark of ImClone Systems Incorporated. Glucophage® and Glucovance® are registered trademarks and Metaglip is a trademark of Merck Santé S.A.S., an associate of Merck KGaA of Darmstadt, Germany, licensed to Bristol-Myers Squibb Company. Avapro®, Avalide® and Plavix® are trademarks of Sanofi-Synthelabo. Tequin® is a registered trademark of Bristol-Myers Squibb licensed from Kyorin Pharmaceutical Co., Ltd., Tokyo, Japan. Sinemet® CR is a registered trademark of Merck & Co., Inc.

Copyright® 1999-2008 Bristol-Myers Squibb Company. Your use of the information on this site is subject to the terms of our Legal Notice and Privacy Policy.

Disclaimer
Copyright © 2005 MarketWatch, Inc. All rights reserved. Please see our Terms of Use.
MarketWatch, the MarketWatch logo, and BigCharts are registered trademarks of MarketWatch, Inc.
Intraday data provided by ComStock, an Interactive Data Company, and subject to the Terms of Use.
Intraday data is at least 15-minutes delayed. All times are ET.
Historical and current end-of-day data provided by FT Interactive Data

SEARCHINDEX